SCHEMBL5973232

SCHEMBL5973232

CC(C)(C)OC(=O)CCC(N)(C(=O)O)C(=O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
FABP5 Q01469 3/20 0.40
FABP7 O15540 2/20 0.40
EPHX2 P34913 1/20 0.37
MDM2 Q00987 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
MDM4 O15151 1/20 0.36
TP53 P04637 1/20 0.36
CASP3 P42574 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173690 1.00 KMT2A (0.41) KMT2AFABP5FABP7EPHX2MDM2
SCHEMBL28124455 0.93 KMT2A (0.42) KMT2AFABP5FABP7EPHX2MDM2
SCHEMBL16060617 0.93 KMT2A (0.42) KMT2AFABP5FABP7EPHX2MDM2
SCHEMBL28124396 0.92 KMT2A (0.43) KMT2AFABP5FABP7EPHX2MDM2
SCHEMBL17079656 0.92 KMT2A (0.43) KMT2AFABP5FABP7EPHX2MDM2
SCHEMBL16061106 0.91 KMT2A (0.45) KMT2AFABP5FABP7EPHX2MDM2
SCHEMBL28124397 0.91 KMT2A (0.45) KMT2AFABP5FABP7EPHX2MDM2
SCHEMBL14054298 0.91 KMT2A (0.41) KMT2AFABP5FABP7EPHX2MDM2
SCHEMBL28125253 0.89 CA1 (0.37) KMT2AFABP5FABP7EPHX2MDM2
SCHEMBL17316183 0.89 CA1 (0.37) KMT2AFABP5FABP7EPHX2MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112390760-B FAK-targeting compound and preparation method and application thereof 北京师范大学 2022-07-29 CN disclosed
CN-112390760-A FAK-targeting compound and preparation method and application thereof 北京师范大学 2021-02-23 CN disclosed
EP-1232183-B1 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LAB (US) 2006-01-18 EP disclosed
US-6753408-B1 DRUGS USED FOR THERAPY ABBVIE INC. 2004-06-22 US disclosed
EP-1232183-A2 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2002-08-21 EP disclosed
WO-2001038347-A2 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2001-05-31 WO disclosed